Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. Επικοινωνία Submitted by Δημήτρης Σπάχος on Δευ, 05/04/2015 - 10:28
